PD-L1 Dako 28-8 and 22C3 assays and Ventana SP263 assay gave comparable results across dedicated platforms for PD-L1 presence.
Durvalumab led to durable responses in patients with heavily treated metastatic non-small cell lung cancer (NSCLC).
Tobacco Companies Seeking To Influence Policy Are Violating the Framework Convention on Tobacco ControlDecember 07, 2016
Tobacco industry representatives are continuing to meet with and are attempting to influence government officials in many countries.
Ceritinib Improves Survival Benefit and Response Rate Compared to Chemotherapy in Patients With NSCLCDecember 07, 2016
First-line ceritinib achieved statistically significant and clinically meaningful improvement in median progression-free survival (PFS).
Adding Ganetespib to Docetaxel Does Not Improve Salvage Therapy Outcomes for Patients With Advanced NSCLCDecember 07, 2016
Addition of ganetespib to docetaxel does not improve efficacy for salvage therapy in patients with advanced stage non-small cell lung cancer (NSCLC).
Atezolizumab demonstrated improved overall survival (OS) compared to docetaxel for patients with unselected non-small cell lung cancer (NSCLC).
The Trans-Pacific Partnership Agreement (TPPA) contains provisions for tobacco products that threaten public health.
Pembrolizumab is associated with a clinically-meaningful improvement in health-related quality of life.
Icotinib demonstrated superior intracranial progression-free survival (iPFS), progression-free survival (PFS), and overall response rate (ORR).
The 8th Edition of the Tumor, Node and Metastasis (TNM) classification of lung cancer will help clinicians refine prognosis.
Osimertinib demonstrated better clinically-meaningful efficacy and a well-characterized safety profile compared to platinum pemetrexed.
Controlling tobacco use is vital to managing the threat it poses to public health, but doing so requires a multi pronged approach.
Although smoking is clearly a major risk factor, pathogenic viruses acquired from consumption of red meat may be a synergistic causative factor.
Double mutations do not significantly decrease overall survival (OS), but do alter progression-free survival (PFS) under first line treatment.
Allowing patients with non-squamous non-small cell lung cancer (NSCLC) to cross over demonstrated a progression-free survival (PFS) benefit.
A randomized phase 2 study found that 30 Grays (Gy) in 1 fraction is equivalent to 60 Gy in 3 fractions in terms of toxicity and survival.
Cabozantinib demonstrated safety and efficacy for treating patients with RET-rearranged lung cancer in an open-label, phase 2 trial.
Brigatinib has shown substantial clinical activity among patients with ALK-positive non-small cell lung cancer (NSCLC) who have brain metastases.
A high percentage of patients with limited-stage small cell lung cancer (SCLC) are elderly, but there is a lack of data concerning the efficacy and safety.
Researchers described "modest success" in a systematic multi-step clinical program to improve tobacco practices.
Institutional-level differences in the quality of care of patients with NSCLC are associated with differences in stage-stratified and overall survival (OS).
Next-generation sequencing (NGS) of circulating DNA (ctDNA) could be used to identify emergent resistance mutations.
Tumor genomes in tobacco users with non-small cell lung cancer (NSCLC) have genetic alterations that are associated with poor outcomes.
Alisertib showed antitumor activity in preclinical in vivo small cell lung cancer (SCLC) models.
Preoperative detection of micrometastases in the mediastinal lymph node (LN) during transcervical extended mediastinal lymphadenectomy (TEMLA).
Researchers discussed efforts to demonstrate that fibroblast growth factor 18 (FGF18) is overexpressed in malignant pleural mesothelioma (MPM) tissues and cell models.
A novel risk-prediction model can identify patients at an increased risk of mortality following surgical treatment.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?